Lapatinib plus chemotherapy or endocrine therapy (CET) versus CET alone in the treatment of HER-2-overexpressing locally advanced or metastatic breast cancer: systematic review and meta-analysis

References

• Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM, editors. GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No 10. Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr. Accessed August 3, 2013.
   Google Scholar
• National Institute for Health and Care Excellence. Lapatinib or trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone-receptor-positive breast cancer that overexpresses HER2. Available from: http://publicationsniceorguk/lapatinib-or-trastuzumab-in-combination-with-an-aromatase-inhibitor-for-the-first-line-treatment-of-ta257. Accessed August 3, 2013.
   Google Scholar
• Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25(1):118–145.
   PubMed Web of Science ®Google Scholar
• Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009;14(4):320–368.
   PubMed Web of Science ®Google Scholar
• Williams C, Brunskill S, Altman D, et al. Cost-effectiveness of using prognostic information to select women with breast cancer for adjuvant systemic therapy. Health TechnolAssess. 2006;10(34):iii-iv, ix-xi, 1–204.
   Google Scholar
• Rasmussen BB, Regan MM, Lykkesfeldt AE, et al. Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1–98 randomised trial. Lancet Oncol. 2008;9(1):23–28.
   PubMed Web of Science ®Google Scholar
• Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006;355(26):2733–2743.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute at the National Institutes of Health. FDA approval for lapatinib ditosylate. Available from: http://www.cancer.gov/cancertopics/druginfo/fda-lapatinib#Anchor-HER6789. Accessed August 3, 2013.
   Google Scholar
• Johnston S, Pippen J Jr, Pivot X, et al. Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol. 2009;27(33):5538–5546.
   PubMed Web of Science ®Google Scholar
• ® Breast Cancer http://wwwnccnorg/professionals/physician_gls/pdf/breastpdf (version 22013).
   Google Scholar
• Guan Z, Xu B, Desilvio ML, et al. Randomized trial of lapatinib versus placebo added to paclitaxel in the treatment of human epidermal growth factor receptor 2-overexpressing metastatic breast cancer. J Clin Oncol. 2013;31(16):1947–1953.
   PubMed Web of Science ®Google Scholar
• Joensuu H, Kellokumpu-Lehtinen PL, Bono P, et al. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. 2006;354(8):809–820.
   PubMed Web of Science ®Google Scholar
• Dickersin K, Scherer R, Lefebvre C. Identifying relevant studies for systematic reviews. BMJ. 1994;309(6964):1286–1291.
   PubMed Web of Science ®Google Scholar
• Clarke M, Oxman AD, editors. Cochrane Reviewers Handbook 4.1.1 (updated December 2000) In: The Cochrane Library, Issue 4, 2000. Oxford, UK: update Software, 2000.
   Google Scholar
• Castro AA, Clark OA, Atallah AN. Optimal search strategy for clinical trials in the Latin American and Caribbean Health Science Literature database (LILACS database): update. Sao Paulo Med J. 1999;117(3):138–139.
   PubMedGoogle Scholar
• Egger M, Smith GD, Altman D. Systematic Reviews in Health Care. London, UK: BMJ Books; 2001.
   Google Scholar
• Parmar MK, Torri V Stewart L. Extracting summary statistic s to perform meta-analyses of the published literature for survival endpoints. Stat Med. 1998;17(24):2815–2834.
   Google Scholar
• Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557–560.
   PubMed Web of Science ®Google Scholar
• Yang K, Wang YJ, Chen XR, Chen HN. Effectiveness and safety of bevacizumab for unresectable non-small-cell lung cancer: a metaanalysis. Clin Drug Investig. 2010;30(4):229—241.
   PubMed Web of Science ®Google Scholar
• Deeks JJ HJ, Altman DG: Analysing and presenting results. In: Higgins JP Green S, editors. Cochrane Handbookfor Systematic Reviews of Interventions. 4.2.6 ed. Chichester, UK: John Wiley and Sons Ltd; 2006.
   Google Scholar
• DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–188.
   PubMedGoogle Scholar
• Egger M, Davey Smith G, Schneider M, Minder C. Bias in metaanalysis detected by a simple, graphical test. BMJ. 1997;315(7109):629–634.
   PubMed Web of Science ®Google Scholar
• McQuay HJ, Moore RA. Using numerical results from systematic reviews in clinical practice. Ann Intern Med. 1997;126(9):712–720.
   PubMed Web of Science ®Google Scholar
• Smeeth L, Haines A, Ebrahim S. Numbers needed to treat derived from meta-analyses - sometimes informative, usually misleading. BMJ. 1999;318(7197):1548–1551.
   PubMed Web of Science ®Google Scholar
• Altman DG, Deeks JJ. Meta-analysis, Simpson’s paradox, and the number needed to treat. BMC Med Res Methodol. 2002;2:3.
   PubMedGoogle Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151(4):W65-W94.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Oliva C, Newstat B, Imwalle B, Geyer CE. Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist. 2010;15(9):924–934.
   PubMed Web of Science ®Google Scholar
• Cameron D, Casey M, Press M, et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008;112(3):533–543.
   PubMed Web of Science ®Google Scholar
• Di Leo A, Gomez HL, Aziz Z, et al. Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol. 2008;26(34):5544–5552.
   PubMed Web of Science ®Google Scholar
• Schwartzberg LS, Franco SX, Florance A, O’Rourke L, Maltzman J, Johnston S. Lapatinib plus letrozole as first-line therapy for HER- 2+ hormone receptor-positive metastatic breast cancer. Oncologist. 2010;15(2):122–129.
   PubMed Web of Science ®Google Scholar
• Yip AY, Tse LA, Ong EY, Chow LW. Survival benefits from lapatinib therapy in women with HER2-overexpressing breast cancer: a systematic review. Anticancer Drugs. 2010;21(5):487–493.
   PubMed Web of Science ®Google Scholar
• Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol. 2002;20(3):719–726.
   PubMed Web of Science ®Google Scholar
• Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010;28(7):1124–1130.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Breast Cancer Treatment (PDQ®). Stage IIIB, inoperable iiic, iv, recurrent, and metastatic breast cancer. Available from: http://wwwcancergov/cancertopics/pdq/treatment/breast/healthprofessional/page7#Section_480. Accessed August 3, 2013.
   Google Scholar
• Riera R, Soarez PC, Puga ME, Ferraz MB. Lapatinib for treatment of advanced or metastasized breast cancer: systematic review. Sao Paulo Med J. 2009;127(5):295–301.
   PubMed Web of Science ®Google Scholar
• Takada M, Higuchi T, Tozuka K, et al. Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. BMC Cancer. 2013;13:241.
   PubMed Web of Science ®Google Scholar
• Wilson MS, Brosens JJ, Schwenen HD, Lam EW. FOXO and FOXM1 in cancer: the FOXO-FOXM1 axis shapes the outcome of cancer chemotherapy. Curr Drug Targets. 2011;12(9):1256–1266.
   PubMed Web of Science ®Google Scholar